StickyCell has developed a Leukocyte Adhesive Function Assay (LAFA) platform. The patent technology provides revolutionary solutions for disease diagnosis, personalised medicines and drug development.
StickyCell has developed and patented the 'LAFA' (leukocyte adhesive function assay) technology for analysing the human immune system and vulnerability to diseases.
Our immune system induces inflammation when circulating leukocytes are activated and become 'stickier' on the blood vessel wall in order to migrate into surrounding tissues. Our cutting-edge LAFA technology in measuring immune cell adhesive function provided a base for a range of new blood testing products, which offer ground-breaking solutions in patient care and drug development.
The activated immune cells adhere to and translocate across the vascular endothelial barrier under high shear stress from the blood flow. Therefore, our Leukocyte Adhesive Function Assay (LAFA) technology uses advanced microfluidic technology to mimic blood microcirculation in vitro, providing an immediate assessment of leukocyte 'stickiness' under physiological conditions. The flow-based imaging and digital analysis technology capture the leukocyte interactions in a shear flow environment.
Millions of people right now are suffering from diseases caused by inflammation. And there will be millions more. Every country and every community is affected by it and pays the price one way or another for the harmful diseases it causes.